Who are gadobenic acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GADOFOSVESET, Primovist, Optimark, MANGAFODIPIR, Omniscan, Prohance.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gadobenic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

gadobenic acid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

gadobenic acid (gadobenic acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Paramagnetic Contrast Agent. Area: Other.

unknown Paramagnetic Contrast Agent Other Live · refreshed every 30 min

Target snapshot

gadobenic acid (gadobenic acid). Gadobenic acid works by altering the magnetic properties of surrounding tissues, allowing for clearer imaging of internal structures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
gadobenic acid TARGET	gadobenic acid		unknown	Paramagnetic Contrast Agent
GADOFOSVESET	GADOFOSVESET	Lantheus Medcl	marketed	Paramagnetic Contrast Agent	2008-01-01
Primovist	GADOXETIC ACID		marketed	Paramagnetic Contrast Agent	2008-01-01
Optimark	GADOVERSETAMIDE	Liebel-Flarsheim	marketed	Paramagnetic Contrast Agent	1999-01-01
MANGAFODIPIR	MANGAFODIPIR		marketed	Paramagnetic Contrast Agent	1997-01-01
Omniscan	GADODIAMIDE	GE HealthCare	marketed	Paramagnetic Contrast Agent [EPC]	1993-01-01
Prohance	GADOTERIDOL	Bracco	marketed	Paramagnetic Contrast Agent	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Paramagnetic Contrast Agent class)

· 3 drugs in this class
Bracco · 1 drug in this class
Lantheus Medcl · 1 drug in this class
Liebel-Flarsheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). gadobenic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/gadobenic-acid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing